Hematologic Malignancy
B-Cell Neoplasm
CI-CAN-00000470Explore in graph →
HematologicNon-malignant2,097 active trials46 approved drugs301 evidence items
- NCIt
- C27907
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000470Explore in graph →
Clinical trials
7,500 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06090162 | LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma(SAKK 38/23) | active not recruiting | N/A | 64 | Swiss Cancer InstituteOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT02682641 | Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL | active not recruiting | Phase 2 | 50 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 |
| Mar 27, 2026 |
| clinicaltrials |
| NCT03236428 | Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma | active not recruiting | Phase 2 | 42 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04835129 | Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma(IMPEDE) | active not recruiting | Phase 2 | 28 | Medical College of WisconsinOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06192888 | A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma | active not recruiting | Phase 1 | 39 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06223516 | Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 1 | 60 | AbbVieINDUSTRY | 4 | Mar 27, 2026 | clinicaltrials |
| NCT02717611 | A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy | active not recruiting | Phase 2 | 60 | Acerta Pharma BVINDUSTRY | 6 | Mar 25, 2026 | clinicaltrials |
| NCT03361852 | Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma | active not recruiting | Phase 1 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04756726 | Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma | active not recruiting | Phase 1 | 224 | C4 Therapeutics, Inc.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04268498 | A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma(ADVANCE) | active not recruiting | Phase 2 | 310 | University of MiamiOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT03534323 | Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS | active not recruiting | Phase 1 / Phase 2 | 55 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT02773030 | A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 466 | CelgeneINDUSTRY | 11 | Mar 20, 2026 | clinicaltrials |
| NCT02405676 | BNHL-2015 for Children or Adolescents in China(BNHL-2015) | active not recruiting | Phase 2 / Phase 3 | 200 | Children's Cancer Group, ChinaNETWORK | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04629729 | FT819 in Subjects With B-cell Malignancies | active not recruiting | Phase 1 | 54 | Fate TherapeuticsINDUSTRY | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06357975 | Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1) | active not recruiting | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Mar 19, 2026 | clinicaltrials |
| NCT02952508 | Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom(CLOVER-WaM) | active not recruiting | Phase 2 | 120 | Cellectar Biosciences, Inc.INDUSTRY | 11 | Mar 18, 2026 | clinicaltrials |
| NCT04904588 | HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide(ACCESS) | active not recruiting | Phase 2 | 300 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04931368 | OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma(OptiMATe) | active not recruiting | Phase 3 | 331 | Klinikum StuttgartOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07480837 | Dynamic Monitoring of Plasma ctDNA for Prognostic Assessment in Patients With B-Cell Non-Hodgkin Lymphoma | active not recruiting | — | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07480850 | Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma | active not recruiting | Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05257083 | A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma(CARTITUDE-6) | active not recruiting | Phase 3 | 759 | Stichting European Myeloma NetworkNETWORK | 16 | Mar 17, 2026 | clinicaltrials |
| NCT05478512 | Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL(VIS) | active not recruiting | Phase 2 | 78 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06353022 | Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma(IFm2022-01) | active not recruiting | Phase 2 | 103 | Nantes University HospitalOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05624554 | A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) | active not recruiting | Phase 3 | 300 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Mar 16, 2026 | clinicaltrials |
| NCT02886065 | A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM | active not recruiting | Phase 1 | 19 | Massachusetts General HospitalOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05767359 | CAR- PRISM (PRecision Intervention Smoldering Myeloma) | active not recruiting | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT00492050 | Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia | active not recruiting | Phase 2 | 46 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT02446457 | Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma | active not recruiting | Phase 2 | 53 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT03336333 | A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL(SEQUOIA) | active not recruiting | Phase 3 | 590 | BeiGeneINDUSTRY | 15 | Mar 9, 2026 | clinicaltrials |
| NCT05540340 | A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant | active not recruiting | Phase 1 | 39 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT04094961 | Ixazomib + Pomalidomide + Dexamethasone In MM | active not recruiting | Phase 1 / Phase 2 | 52 | Omar Nadeem, MDOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04656951 | Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse(GMMG-DADA) | active not recruiting | Phase 2 | 67 | University of CologneOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04802356 | Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients | active not recruiting | Phase 2 | 50 | PETHEMA FoundationOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT02659293 | Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma | active not recruiting | Phase 3 | 180 | University of ChicagoOTHER | 2 | Mar 4, 2026 | clinicaltrials |
| NCT03070327 | BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma | active not recruiting | Phase 1 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT03729804 | Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)((COBRA)) | active not recruiting | Phase 3 | 250 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT03741127 | Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101 | active not recruiting | Phase 1 | 100 | Poseida Therapeutics, Inc.INDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05479994 | Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | active not recruiting | Phase 2 | 100 | BeiGeneINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT03789240 | Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma | active not recruiting | Phase 2 | 33 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2026 | clinicaltrials |
| NCT05546268 | Study of Oral MRT-2359 in Selected Cancer Patients | active not recruiting | Phase 1 / Phase 2 | 174 | Monte Rosa Therapeutics, IncINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT05271630 | Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant | active not recruiting | — | 69 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT03589222 | SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma | active not recruiting | Phase 2 | 62 | PETHEMA FoundationOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04270175 | Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab | active not recruiting | Phase 2 | 15 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04624633 | Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL | active not recruiting | Phase 2 | 29 | Jennifer R. Brown, MD, PhDOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT04764942 | Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial | active not recruiting | Phase 1 / Phase 2 | 39 | Mayo ClinicOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT00378105 | Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 68 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT05587972 | Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring | active not recruiting | N/A | 100 | Carevive Systems, Inc.INDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT05577000 | Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 1 | 5 | Thomas Martin, MDOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT04842877 | Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma | active not recruiting | Phase 2 | 141 | The Lymphoma Academic Research OrganisationOTHER | 2 | Feb 19, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Mar 30, 2026source: clinicaltrials